Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
1.150
-0.020 (-1.71%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Inovio Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 0.07 | 0.22 | 0.83 | 10.26 | 1.77 | Upgrade
|
| Revenue | 0.07 | 0.22 | 0.83 | 10.26 | 1.77 | Upgrade
|
| Revenue Growth (YoY) | -69.99% | -73.83% | -91.89% | 478.24% | -76.05% | Upgrade
|
| Cost of Revenue | 54.21 | 75.62 | 84.69 | 187.65 | 249.24 | Upgrade
|
| Gross Profit | -54.14 | -75.4 | -83.86 | -177.39 | -247.47 | Upgrade
|
| Selling, General & Admin | 32.68 | 37 | 42.88 | 76.19 | 53.75 | Upgrade
|
| Operating Expenses | 32.68 | 37 | 42.88 | 76.19 | 53.75 | Upgrade
|
| Operating Income | -86.82 | -112.4 | -126.74 | -253.57 | -301.22 | Upgrade
|
| Interest Expense | - | -0.18 | -1.22 | -1.25 | -1.94 | Upgrade
|
| Interest & Investment Income | 2.42 | 4.77 | 8.13 | 4.78 | 3.36 | Upgrade
|
| Earnings From Equity Investments | 0.49 | -1.17 | 0.77 | -4.06 | -0.99 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.26 | 1.55 | 0.09 | 0.17 | 0.35 | Upgrade
|
| EBT Excluding Unusual Items | -85.17 | -107.43 | -118.96 | -253.94 | -300.43 | Upgrade
|
| Impairment of Goodwill | - | - | -10.51 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.22 | 0.17 | 1.04 | -11.88 | -3.23 | Upgrade
|
| Asset Writedown | - | - | -1.98 | - | - | Upgrade
|
| Legal Settlements | - | - | -4.7 | -14 | - | Upgrade
|
| Pretax Income | -84.95 | -107.25 | -135.12 | -279.82 | -303.66 | Upgrade
|
| Earnings From Continuing Operations | -84.95 | -107.25 | -135.12 | -279.82 | -303.66 | Upgrade
|
| Net Income | -84.95 | -107.25 | -135.12 | -279.82 | -303.66 | Upgrade
|
| Net Income to Common | -84.95 | -107.25 | -135.12 | -279.82 | -303.66 | Upgrade
|
| Shares Outstanding (Basic) | 47 | 27 | 22 | 20 | 17 | Upgrade
|
| Shares Outstanding (Diluted) | 47 | 27 | 22 | 20 | 17 | Upgrade
|
| Shares Change (YoY) | 72.63% | 22.49% | 11.51% | 14.27% | 34.62% | Upgrade
|
| EPS (Basic) | -1.81 | -3.95 | -6.09 | -14.07 | -17.45 | Upgrade
|
| EPS (Diluted) | -1.81 | -3.95 | -6.09 | -14.07 | -17.45 | Upgrade
|
| Free Cash Flow | -88.92 | -104.56 | -124.69 | -217.18 | -216.94 | Upgrade
|
| Free Cash Flow Per Share | -1.90 | -3.85 | -5.62 | -10.92 | -12.47 | Upgrade
|
| Operating Margin | -132871.32% | -51616.91% | -15233.26% | -2470.93% | -16972.34% | Upgrade
|
| Profit Margin | -130000.00% | -49254.27% | -16239.87% | -2726.67% | -17109.87% | Upgrade
|
| Free Cash Flow Margin | -136074.45% | -48019.06% | -14986.17% | -2116.34% | -12223.61% | Upgrade
|
| EBITDA | -85.4 | -110.65 | -123.98 | -249.42 | -297.66 | Upgrade
|
| D&A For EBITDA | 1.42 | 1.75 | 2.77 | 4.15 | 3.56 | Upgrade
|
| EBIT | -86.82 | -112.4 | -126.74 | -253.57 | -301.22 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.